AzTrials
AzTrials

Cardiovascular DiseasesEPIPOPNCT02991703

Simplified Pulse Wave Velocity Measurement, Validation Study of the pOpmètre in Children

A study testing pOpmètre® and Sphygmocor in people with Cardiovascular Diseases and Arteriosclerosis, run by Nantes University Hospital at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Arterial stiffness is an important marker of cardiovascular risk. It is measured by pulse wave velocity. The reference device to measure pulse wave velocity is the Sphygmocor which uses applanation tonometry. It is used in adults and children. Read more about this study

Who is it for?
Ages 4 to 8 years
What is being tested?
pOpmètre® and Sphygmocor
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteFrance
Study dates
14 Dec 2016to 6 Jul 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 8 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • children between 4 and 8 years old hospitalized in the Mother and Children Hospital in Nantes during the study period.

Who cannot join

  • Vasoconstrictor treatment,
  • compressive bandage on the measured area,
  • peripheral venous access on the measured side,
  • vascular surgery or pathology on the measured area,
  • significant pain or agitation,
  • parental or legal representative disapproval,
  • child disapproval.

Trial locations and contacts

1 site in 1 country.

France1 site

  • CHU de Nantes

    Nantes, 44093

Other trials in France

About this study

Arterial stiffness is an important marker of cardiovascular risk. It is measured by pulse wave velocity. The reference device to measure pulse wave velocity is the Sphygmocor which uses applanation tonometry. It is used in adults and children. An easier method called pOpmètre using saturation sensors is validated in adults but not in children. The objective of this study is to compare the pulse wave velocity values measured with the pOpmètre® with those of the SphygmoCor® to validate the pOpmètre in children between 4 and 8 years old.

Read the detailed description

Prematurity is associated with an increased risk of developing cardio-vascular diseases in adulthood : a low birth weight linked to prematurity is correlated to a higher coronary disease mortality rate, a higher blood pressure level in adulthood, to abnormal glucose metabolism regulation, and to signs of nephron reduction. An independent marker of cardiovascular risk is arterial stiffness: it is associated with a higher risk of major cardiovascular events including stroke, acute coronary syndrome and complications of end-stage renal disease. It is measured by pulse wave velocity which is the gold standard in adulthood. Pulse wave velocity is also correlated to cardiovascular risk in childhood. National cohort EPIPAGE II is made of 4290 premature babies born in 2011. A study is scheduled at 5 years old and a half including a medical examination and a neuropsychological evaluation. An ancillary study lengthening medical consultation for 15 minutes is scheduled with 750 to 1000 of these children for a more precise vascular evaluation including pulse wave velocity. Different methods can be used to measure pulse wave velocity in children: these include applanation tonometry devices such as the SphygmoCor ® system. Its reference values are well known in adulthood and were determined more recently in childhood. It is the reference device but it is expensive, can be used only in expert health centres and time of measurement is long. In children, an easier-to-use and faster device would be more advantageous. The pOpmètre® uses 2 distal oxygen saturation sensors on finger and toe to deduce pulse wave velocity. This device has already been validated in adults. The aim of this study is to validate the pOpmètre in children between 4 and 8 years old. In that purpose, patients are installed in the supine position, at rest. The child's mensurations are measured. The two pOpmètre sensors are put on finger and toe. Blood pressure is measured by an armband on the right limb. Then another armband is put around the thigh and a tonometer is applied on the right carotid which allows pulse wave velocity measuring by the Sphygmocor. Pulse wave velocity is measured with the pOpmètre using the time delay between finger pulse signal and toe pulse signal. The values got with the two devices are compared using a Bland and Altman graph. The pOpmètre is considered to be validated if the 95% confidence interval of the bias is included between -0.5 m/sec and 0.5 m/sec that is about 10% of the normal value at that age (5.0 m/s +/-0.13).

Being tested
pOpmètre®, Sphygmocor
Keywords
Arterial stiffness, pulse wave velocity, Sphygmocor, applanation tonometry, pOpmètre, children, EPIPAGE cohort
Medical subject headings
Cardiovascular Diseases, Arteriosclerosis, Atherosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • pOpmètre®Device

    the pOpmètre® uses saturation sensors,

  • SphygmocorDevice

    the Sphygmocor uses applanation tonometry

Study groups in NCT02991703
Study groupRoleWhat they receive
SphygmoCor®Active comparatorNot described
Receives: Device: Sphygmocor
pOpmètre®ExperimentalNot described
Receives: Device: pOpmètre®

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Difference between the two simultaneous measurements of velocity of the pulse wave by the pOpmeter® and the Sphygmocor®.

    Measured: Day One

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Dec 2016 (estimated)
  2. Study start14 Dec 2016
  3. Primary completion6 Jul 2017
  4. Study completion6 Jul 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02991703
Sponsor's protocol ID
RC16_0161
Acronym
EPIPOP
Status last verified
May 2018
First submitted
23 Nov 2016
Last updated
14 Sep 2026
Results posted
No
Data monitoring committee
No

Publications

  • Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006 Feb 7;113(5):664-70. doi: 10.1161/CIRCULATIONAHA.105.579342.

    PubMed 16461839

  • Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR, Hayman L, Jacobson M, Mahoney L, Mietus-Snyder M, Rocchini A, Steinberger J, McCrindle B; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension. 2009 Nov;54(5):919-50. doi: 10.1161/HYPERTENSIONAHA.109.192639. Epub 2009 Sep 3.

    PubMed 19729599

  • Ancel PY, Goffinet F; EPIPAGE 2 Writing Group. EPIPAGE 2: a preterm birth cohort in France in 2011. BMC Pediatr. 2014 Apr 9;14:97. doi: 10.1186/1471-2431-14-97.

    PubMed 24716860

  • Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 2010 Oct;31(19):2338-50. doi: 10.1093/eurheartj/ehq165. Epub 2010 Jun 7.

    PubMed 20530030

  • Reusz GS, Cseprekal O, Temmar M, Kis E, Cherif AB, Thaleb A, Fekete A, Szabo AJ, Benetos A, Salvi P. Reference values of pulse wave velocity in healthy children and teenagers. Hypertension. 2010 Aug;56(2):217-24. doi: 10.1161/HYPERTENSIONAHA.110.152686. Epub 2010 Jun 21.

    PubMed 20566959

  • Curcio S, Garcia-Espinosa V, Arana M, Farro I, Chiesa P, Giachetto G, Zocalo Y, Bia D. Growing-Related Changes in Arterial Properties of Healthy Children, Adolescents, and Young Adults Nonexposed to Cardiovascular Risk Factors: Analysis of Gender-Related Differences. Int J Hypertens. 2016;2016:4982676. doi: 10.1155/2016/4982676. Epub 2016 Feb 18.

    PubMed 26989504

  • Alivon M, Vo-Duc Phuong T, Vignon V, Bozec E, Khettab H, Hanon O, Briet M, Halimi JM, Hallab M, Plichart M, Mohammedi K, Marre M, Boutouyrie P, Laurent S. A novel device for measuring arterial stiffness using finger-toe pulse wave velocity: Validation study of the pOpmetre(R). Arch Cardiovasc Dis. 2015 Apr;108(4):227-34. doi: 10.1016/j.acvd.2014.12.003. Epub 2015 Feb 11.

    PubMed 25682547

  • Bichali S, Bruel A, Boivin M, Roussey G, Romefort B, Roze JC, Allain-Launay E. Simplified pulse wave velocity measurement in children: Is the pOpmetre valid? PLoS One. 2020 Mar 27;15(3):e0230817. doi: 10.1371/journal.pone.0230817. eCollection 2020.

    PubMed 32218581

Questions about this trial

What is this clinical trial studying?

A study testing pOpmètre® and Sphygmocor in people with Cardiovascular Diseases and Arteriosclerosis, run by Nantes University Hospital at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Difference between the two simultaneous measurements of velocity of the pulse wave by the pOpmeter® and the Sphygmocor®. (time frame: Day One). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02991703, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in